JPS6360926A - Cold remedy - Google Patents
Cold remedyInfo
- Publication number
- JPS6360926A JPS6360926A JP61206295A JP20629586A JPS6360926A JP S6360926 A JPS6360926 A JP S6360926A JP 61206295 A JP61206295 A JP 61206295A JP 20629586 A JP20629586 A JP 20629586A JP S6360926 A JPS6360926 A JP S6360926A
- Authority
- JP
- Japan
- Prior art keywords
- antipyretic analgesic
- bromhexine hydrochloride
- cold
- hydrochloride
- active ingredients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003907 antipyretic analgesic agent Substances 0.000 claims abstract description 12
- 229960002335 bromhexine hydrochloride Drugs 0.000 claims abstract description 11
- YRSGDLIATOURQO-UHFFFAOYSA-N ethyl 4-acetyl-5-oxohexanoate Chemical compound CCOC(=O)CCC(C(C)=O)C(C)=O YRSGDLIATOURQO-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960000514 ethenzamide Drugs 0.000 claims abstract description 6
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960001680 ibuprofen Drugs 0.000 claims abstract description 3
- 229940124579 cold medicine Drugs 0.000 claims description 14
- 206010036790 Productive cough Diseases 0.000 abstract description 10
- 208000024794 sputum Diseases 0.000 abstract description 10
- 210000003802 sputum Anatomy 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- LIAWQASKBFCRNR-UHFFFAOYSA-N Bucetin Chemical compound CCOC1=CC=C(NC(=O)CC(C)O)C=C1 LIAWQASKBFCRNR-UHFFFAOYSA-N 0.000 abstract description 3
- 229960005470 bucetin Drugs 0.000 abstract description 3
- 206010011224 Cough Diseases 0.000 abstract description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 2
- 230000000954 anitussive effect Effects 0.000 abstract description 2
- 239000000739 antihistaminic agent Substances 0.000 abstract description 2
- 229940124584 antitussives Drugs 0.000 abstract description 2
- 208000026435 phlegm Diseases 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 239000011782 vitamin Substances 0.000 abstract description 2
- 229940088594 vitamin Drugs 0.000 abstract description 2
- 229930003231 vitamin Natural products 0.000 abstract description 2
- 235000013343 vitamin Nutrition 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract 2
- 229940124623 antihistamine drug Drugs 0.000 abstract 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 12
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 229920000084 Gum arabic Polymers 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000978776 Senegalia senegal Species 0.000 description 4
- 239000000205 acacia gum Substances 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229960005489 paracetamol Drugs 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- -1 fatty acid esters Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000000095 emetic effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical class [H]O* 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は去痰作用の増強された感冒薬に関し、更に詳し
くは、喀痰粘度低下作用を有する感冒薬に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention relates to a cold medicine with enhanced expectorant action, and more particularly to a cold medicine with a sputum viscosity-lowering action.
従来より多棟の感冒薬が知られているが、いずれも喀痰
溶解作用が弱く満足できる効果は得られていなかった。A number of cold medicines have been known for some time, but none of them had a satisfactory sputum-dissolving effect and had no satisfactory effect.
塩酸プロムヘキンンは、去痰薬として広く用いられてお
り、気道粘液溶解作用により気道を清浄化し、かつ催吐
作用がないのが特徴とされている。Promhequine hydrochloride is widely used as an expectorant, and is characterized by its ability to cleanse the respiratory tract through its mucolytic action and to have no emetic effect.
この塩酸ブロムヘキシンを有効成分として含有する感冒
薬は知られていない。There is no known cold medicine containing this bromhexine hydrochloride as an active ingredient.
いずれの感冒薬も喀痰溶解作用が弱く満足できる効果は
得られていなかった。None of the cold medicines had a weak sputum-dissolving effect, and no satisfactory effect was obtained.
本発明者らは、喀痰溶解作用の増強を目的とし何発した
結果、塩酸ブロムヘキノンとある種の解熱鎮痛薬とを配
合することにより、喀痰溶解作用が増強されることを見
出し、本発明を完成した。The inventors of the present invention discovered that the sputum-dissolving effect can be enhanced by combining bromhequinone hydrochloride with a certain type of antipyretic analgesic after several shots aimed at enhancing the sputum-dissolving effect, and have completed the present invention. did.
本発明は、有効成分として、塩酸プロムヘキ／ンと解熱
鎮痛薬とを含有することを特徴とする感冒薬である。The present invention is a cold medicine characterized by containing promhequine hydrochloride and an antipyretic analgesic as active ingredients.
本発明の感冒薬において、解熱鎮痛薬とはアセアミノ
ド△フェノン、ブセチン、エテンザミドまたはイブプロ
フェンである。In the cold medicine of the present invention, the antipyretic analgesic is aceminodo△phenone, busetin, ethenzamide, or ibuprofen.
本発明の感冒薬は塩酸ブロムヘキノンと解ｐ８．鎮痛薬
の他に必要に応じて、抗ヒスタミン薬、鎮咳薬、ビタミ
ン等の補助薬剤を適宜に配合しても良い。The cold medicine of the present invention is bromhequinone hydrochloride and solution p8. In addition to analgesics, auxiliary drugs such as antihistamines, antitussives, and vitamins may be appropriately blended as necessary.
解熱鎮痛薬を塩酸プロムヘキン７１重量部に対して１８
〜１２５重量部、好ましくは３７〜７５重量部配合する
。この範囲を外れる時は所期の効果を奏し難くなる。Antipyretic analgesic: 18 parts by weight for 71 parts by weight of promhequin hydrochloride
~125 parts by weight, preferably 37 to 75 parts by weight. When it is outside this range, it becomes difficult to achieve the desired effect.
本発明の感冒薬は風邪の諸症状、咳漱、痰の緩和に有効
である。The cold medicine of the present invention is effective in alleviating various cold symptoms, cough and phlegm.
また本発明の感冒薬は通常、成人に対して１日当り、有
効成分として４５０〜１５００ηを１回ないし、数回に
分けて経口投与することができる。Further, the cold medicine of the present invention can be orally administered to adults in an amount of 450 to 1500 η per day as the active ingredient once or in divided doses.
この投与量は年齢、体重、病状により適宜増減すること
ができる。This dosage can be increased or decreased as appropriate depending on age, body weight, and medical condition.
更にまた、本発明の感冒薬は錠剤、顆粒剤、粉剤、カプ
セル剤などの経口投与タイプの製剤として用いる。Furthermore, the cold medicine of the present invention is used in the form of oral administration type preparations such as tablets, granules, powders, and capsules.
これらの製剤は、常法により調整することができる。製
剤の調製に使用できる担体としては、乳糖、澱粉、砂糖
、マンニトール、結晶セルロース（例えば、アビセル（
登録商標、旭化成工業株式会社製）など）などの賦形剤
：ヒドロキシグロビルセルロース、カルボキシメチルセ
ルロース、ゼラチン、アラビアゴムなどの結合剤：グリ
セリン、エチレングリコールなどの湿潤剤：カルボキシ
メチルセルロースカルシウム、低置換ヒドロキシグロピ
ルセルロースなどの崩壊剤：ポリオキシソルビタン脂肪
酸エステルなどの非イオン界面活性剤ニステアリン酸カ
ルシウム、ステアリン酸マグネシウム、タルク、ポリエ
チレングリコール、ポリオキシエチレンソルピノト、ソ
ルビタンエステル、メタ水酸化アルミニーラム、寒天、
トラガントなどがあり、この他必要に応じて、溶解補助
剤、緩衝剤、保存剤、香料、着色剤、矯味剤などを使用
することができる。These formulations can be prepared by conventional methods. Carriers that can be used in the preparation of formulations include lactose, starch, sugar, mannitol, crystalline cellulose (e.g. Avicel (
Excipients such as hydroxyglobil cellulose, carboxymethyl cellulose, gelatin, gum arabic, etc. Wetting agents such as glycerin, ethylene glycol, etc. Wetting agents: carboxymethyl cellulose calcium, low-substituted hydroxy Disintegrants such as glopy cellulose: nonionic surfactants such as polyoxysorbitan fatty acid esters, calcium nistearate, magnesium stearate, talc, polyethylene glycol, polyoxyethylene sorpinoto, sorbitan esters, aluminum metahydroxide, agar,
tragacanth, etc. In addition, solubilizing agents, buffering agents, preservatives, fragrances, coloring agents, flavoring agents, etc. can be used as necessary.
本発明の感冒薬は塩酸ブロムヘキンンと前記解熱鎮痛薬
との組合わせによる相乗効果によって、塩酸ブロムヘキ
シンの喀痰粘度低下作用が増強されるもので、効能の優
れた医薬品として有用である。The cold medicine of the present invention enhances the sputum viscosity-lowering effect of bromhexine hydrochloride due to the synergistic effect of the combination of bromhequine hydrochloride and the above-mentioned antipyretic analgesic, and is useful as a highly effective pharmaceutical.
以下、試験例および実施例を挙げて、本発明を具体的に
説明する。The present invention will be specifically described below with reference to Test Examples and Examples.
試験例
（試験動物）
日本白色ウサギ（体重２〜２．５ Ｋｇ）を１群５匹以
上使用した。Test Example (Test Animal) Five or more Japanese white rabbits (body weight 2-2.5 kg) were used in each group.
（検体）
塩酸ブロムヘキシ７１２■とアセトアミノフェン、ブセ
チン、エテンザミドのそれぞれ９００■、１０００■、
１５００■を用時５％アラビアゴム水溶ｅ、５−に懸濁
したものを使用した。(Sample) Bromhexychloride 712■ and acetaminophen, busetin, ethenzamide 900■ and 1000■, respectively.
1500 ml was suspended in 5% aqueous gum arabic e,5- before use.
また、対照群として以下の５％アラビアゴム懸濁水溶液
５ゴを使用した。Further, as a control group, the following 5% aqueous suspension of gum arabic solution 5go was used.
対照薬Ａ：５％アラビアゴム水溶液のみ〃 Ｂ；塩酸ブ
ロムヘキシン １２η
〃 Ｃ；アセトアミノフェン ９００〜〃 Ｄ；ブセチ
ン １０００■
対照薬Ｅ；エテンザミド １５００η（方法）
検体をそれぞれ別個のウレタン麻酔下のウサギにシリコ
ンチューブを介して経口投与し、その２時間後に動物の
気道内からベリーとボイド（Ｐｅｒｒｙａｎｄ Ｂｏｙ
ｄ ）の方法〔ジャーナル ファーマコロジー アンド
エクスベリメンタル テラピ、クス（Ｊ、 Ｐｈａｒ
ｍａｃｏｌ、 ｅｘｐ、 Ｔｈｅｒ、）、第７３巻、第
６５頁、１９４１年〕により喀痰を採取し、それぞれの
粘度を回転粘度計にて測定した。Control drug A: 5% aqueous gum arabic solution only〃 B: Bromhexine hydrochloride 12η〃 C: Acetaminophen 900~〃 D: Bucetin 1000■ Control drug E: Ethenzamide 1500η (Method) Each specimen was placed in a separate rabbit under urethane anesthesia. It was orally administered via a silicone tube, and two hours later, Perry and Boy was administered from the respiratory tract of the animal.
d) method [Journal of Pharmacology and Experimental Therapy,
macol, exp, Ther.), Vol. 73, p. 65, 1941], and the viscosity of each was measured using a rotational viscometer.
（結果） 試験結果を表１に示す。(result) The test results are shown in Table 1.
塩酸ブロムヘキシン自体は軽度の喀痰粘度低下作用を示
し、解熱鎮痛剤単独投与では喀痰粘度に対し何ら作用を
示していないが、塩酸ブロムヘキシンと解熱鎮痛剤とを
配合することにより、顕著な喀痰粘度の低下作用が認め
られた。Bromhexine hydrochloride itself shows a mild sputum viscosity-lowering effect, and when administered alone as an antipyretic analgesic, it does not show any effect on sputum viscosity; however, by combining bromhexine hydrochloride and an antipyretic analgesic, a significant decrease in sputum viscosity is observed. The effect was observed.
表１
ｃｐ：センチボワーズ
実施例 １
塩酸ブロムヘキシン ０．４ｆ、アセトアミノフェン
３０り、アビセル ７４．５ Ｆおよび乳糖９０２を使
用して、湿式造粒法により顆粒を調製し、これにステア
リン酸マグネ７ウム ５１を加えて打錠し、重量２００
〜の錠剤１０００錠を得た。Table 1 cp: Centiboise Example 1 Bromhexine hydrochloride 0.4f, acetaminophen
Granules were prepared by a wet granulation method using Avicel 74.5 F and lactose 902, and 71% magnesium stearate was added to the granules and tableted to a weight of 200.
1000 tablets of ~ were obtained.
実施例 ２
塩酸フロムヘキンン α４２、ブセチン ３５９、乳糖
２６１．６ｔＳ ヒドロキシプロピルセルロース
５２を使用して湿式造粒法により顆粒３００２を得た。Example 2 Fromhequin hydrochloride α42, Bucetin 359, Lactose 261.6tS Hydroxypropyl cellulose
Granules 3002 were obtained by a wet granulation method using No. 52.
実施例 ３
塩酸ブロムヘキシン ０．４Ｆ、エテンザミド５０２、
乳糖 １４６２、ヒドロキンプロピルセルロース ３２
を均一に混合し、これを２００ｒｒＩｇずつ分包して、
散剤１０００包を得た。Example 3 Bromhexine hydrochloride 0.4F, ethenzamide 502,
Lactose 1462, Hydroquinepropylcellulose 32
Mix it evenly, divide it into 200rrIg portions,
1000 packets of powder were obtained.
実施例 ４
塩酸ブロムヘキソン ０．４り、アセトアミノフェン
３０２、アビセル １６３．６Ｆ、ヒドロキシプロピル
セルロース ３２、ステア１に／酸マグネシウム ３１
を均一に混合した。この混合粉体を１号カプセルに２０
０■ずつ充填してカプセル１０００個を得た。Example 4 Bromhexone hydrochloride 0.4%, acetaminophen
302, Avicel 163.6F, Hydroxypropyl cellulose 32, Stear 1/magnesium acid 31
were mixed uniformly. Put this mixed powder into No. 1 capsule for 20
1,000 capsules were obtained by filling 0.0 cm each.
Claims (1)
とを含有することを特徴とする感冒薬。 ２）解熱鎮痛薬がアセトアミノフェノン、プセチン、エ
テンザミドまたはイブプロフェンである特許請求の範囲
第１項の感冒薬。[Scope of Claims] 1) A cold medicine characterized by containing bromhexine hydrochloride and an antipyretic analgesic as active ingredients. 2) The cold medicine according to claim 1, wherein the antipyretic analgesic is acetaminophenone, psetin, ethenzamide, or ibuprofen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20629586A JP2501201B2 (en) | 1986-09-02 | 1986-09-02 | Cold medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20629586A JP2501201B2 (en) | 1986-09-02 | 1986-09-02 | Cold medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6360926A true JPS6360926A (en) | 1988-03-17 |
| JP2501201B2 JP2501201B2 (en) | 1996-05-29 |
Family
ID=16520935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP20629586A Expired - Lifetime JP2501201B2 (en) | 1986-09-02 | 1986-09-02 | Cold medicine |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2501201B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996033704A1 (en) * | 1995-04-26 | 1996-10-31 | Taisho Pharmaceutical Co., Ltd. | Preparation for oral administration |
| JP2009155349A (en) * | 2009-04-16 | 2009-07-16 | Daiichi Sankyo Co Ltd | Medicinal composition containing bromhexine |
-
1986
- 1986-09-02 JP JP20629586A patent/JP2501201B2/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996033704A1 (en) * | 1995-04-26 | 1996-10-31 | Taisho Pharmaceutical Co., Ltd. | Preparation for oral administration |
| JP2009155349A (en) * | 2009-04-16 | 2009-07-16 | Daiichi Sankyo Co Ltd | Medicinal composition containing bromhexine |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2501201B2 (en) | 1996-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR0164435B1 (en) | A pharmaceutical composition for the treatment of obesity | |
| TW576743B (en) | Extended release formulations of erythromycin derivatives | |
| KR100891887B1 (en) | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient | |
| JP4365107B2 (en) | Pharmaceutical composition | |
| JP4365106B2 (en) | Pharmaceutical combination | |
| FI101040B (en) | A process for the preparation of an oral dosage form for the treatment of central dopamine deficiency states | |
| CN100389751C (en) | Swallow tablet comprising paracetamol | |
| JPH0635382B2 (en) | Uses of fluoxetine as an anxiolytic | |
| US4888343A (en) | Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process | |
| JP2943247B2 (en) | Hypnosis / Sedative | |
| KR100709528B1 (en) | Drug composition for blood sugar control | |
| JPH02188523A (en) | Remedy for apnea in sleeping | |
| DK165966B (en) | IMPROVED PIROXICAM CONTAINING ANTI-INFLAMMATORY PREPARATION | |
| JPH0656677A (en) | Antacid composition | |
| KR101697773B1 (en) | Modified release composition comprising doxofylline | |
| JPS6360926A (en) | Cold remedy | |
| CZ79593A3 (en) | Antitussive preparation | |
| JP2000229853A (en) | Menstruation pain-improving composition | |
| JP6087988B2 (en) | Composition for inhibiting nasal secretion | |
| JP2019210262A (en) | Orally disintegrating tablet | |
| JP4710240B2 (en) | Pharmaceutical composition | |
| JP2003095981A (en) | Medicine composition | |
| JP2005289906A (en) | Medicinal composition | |
| JP2018076312A (en) | Pharmaceutical composition containing acetaminophen, isopropylantipyrine and ginger-derived components | |
| JPS61134315A (en) | Antipyretic and analgesic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |